Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05089695

Helmet NIV vs. CPAP vs. High-flow Nasal Oxygen in Hypoxemic Respiratory Failure

Multicenter, open label, three-arm randomized trial to assess the effect of helmet noninvasive ventilation vs. helmet continuous positive airway pressure vs. high-flow nasal oxygen on the rate of endotracheal intubation of patients with acute moderate-to-severe hypoxemic respiratory failure

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gemelli

Rome, Italy

Location status: Recruiting

Location contact

Domenico L Grieco, MD

CONTACT

[email protected]

About this study

The optimal initial management of acute hypoxemic respiratory failure is uncertain. Helmet noninvasive ventilation and high-flow nasal oxygen appear as the most promising techniques in this setting. Recently, the first head-to-head randomized trial compared first-line continuous treatment with helmet pressure support ventilation with specific settings (PEEP=12 cmH2O pressure and pressure support=10-12 cmH2O) vs. high-flow nasal oxygen alone in patients with moderate-to-severe hypoxemic respiratory failure. Results showed no significant inter-group difference in the days free of respiratory support at 28 days, but lower intubation rate and increased 28-day invasive ventilation-free days in the helmet group. Use of helmet noninvasive ventilation is less frequent than use of helmet continuous positive airway pressure, which is simpler to use.

The investigators designed an open-label, multicentre randomized trial to assess the effect of helmet pressure support ventilation and continuous airway pressure as compared to high-flow nasal oxygen on the intubation rate of patients with moderate-to-severe hypoxemic respiratory failure in the intensive care unit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Acute symptoms of respiratory failure PaO2/FiO2 ratio ≤ 200; PaCO2≤45mmHg; Absence of history of chronic respiratory failure or moderate to severe cardiac insufficiency (NYHA>2 or left ventricular ejection fraction<50%); Informed consent

Patients that have already received NIV, CPAP continuously for more than 24 hours before the screening visit will be excluded.

Other Exclusion Criteria:

  • Pregnancy;
  • Exacerbation of asthma or chronic obstructive pulmonary disease;
  • Hypercapnia (PaCO2>45 mmHg) with or without respiratory acidosis;
  • More than 2 organ failures, including the lung.
  • Documented pneumothorax;
  • Clinical diagnosis of Cardiogenic pulmonary edema;
  • Haemodynamic instability (Systolic blood pressure<90 mmHg or mean arterial pressure<65mmHg) and/or lactic acidosis (lactate>5 mmol/L) and/or clinically diagnosed Shock requiring administration of vasoactive agents (norepinephrine>0.1 mcg/Kg/min);
  • Metabolic Acidosis (pH <7.30 with normal- or hypo-carbia);
  • Chronic kidney failure requiring dialysis before ICU admission;
  • Chronic hypoxemic respiratory failure requiring long-term oxygen therapy;
  • Altered neurological status that requires immediate intubation and/or making the patient uncooperative;
  • Urgent need for endotracheal intubation, according to the decision of the attending physician;
  • Do not intubate order;
  • Decision of withdrawal of life-sustaining therapy;
  • Thoracic or abdominal surgery in the previous 7 days;
  • Any condition that makes the patient very likely to require endotracheal intubation due to a reason different from respiratory failure;
  • Recent head surgery or anatomy that prevent the application of helmet or HFNC to patient's face.

Treatment and study plan

Noninvasive respiratory support

Device

Treatment of acute hypoxemic respiratory failure

Primary outcomes

  1. Rate of Endotracheal intubation

    Time frame: 28 days

    The proportion of patients requiring endotracheal intubation according to predefined criteria

Secondary outcomes

  1. Days free of invasive mechanical ventilation at day 28

    Time frame: 28 days

    The number of days in which patients do not receive mechanical ventilation within 28 days from randomization

  2. Days free of invasive mechanical ventilation at day 60

    Time frame: 60 days

    The number of days in which patients do not receive mechanical ventilation within 60 days from randomization

  3. Days free of invasive mechanical ventilation at day 90

    Time frame: 90 days

    The number of days in which patients do not receive mechanical ventilation within 60 days from randomization

  4. Rate of In-intensive care unit mortality

    Time frame: 90 days

    All-cause mortality, assessed at the discharge from the intensive care unit

  5. Rate of In-hospital care unit mortality

    Time frame: 90 days

    All-cause mortality, assessed at the discharge from the hospital

  6. Rate of 90-day mortality

    Time frame: 90 days

    All-cause 90-day mortality

  7. 90-day ICU free days

    Time frame: 90 days

    The days not spent in the intensive care unit by the patient on a 90-day basis

  8. 90-day hospital free days

    Time frame: 90 days

    The days not spent in the hospital by the patient on a 90-day basis

  9. Incidence of pneumonia

    Time frame: 90 days

    Incidence of pneumonia, diagnosed after the treatment start and during the ICU stay

  10. Incidence of shock

    Time frame: 90 days

    Incidence of shock, diagnosed after treatment start and during the ICU stay

  11. Incidence of barotrauma

    Time frame: 90 days

    Incidence of barotrauma, defined as pneumothorax o pneumomediastinum after treatment start and during the ICU stay

Other outcomes

  1. Safety endpoint-causes of endotracheal intubation

    Time frame: 28 days

    Among patients meeting the primary endpoint, the cause of noninvasive treatment failure (as defined by the predefined intubation criteria)

  2. Safety endpoint-time to treatment failure

    Time frame: 28 days

    In patients meeting the primary endpoint, the time (hours) from randomization to intubation

Study contacts

Contact information is provided by the study sponsor or research team.

Domenico Luca Grieco, MD

CONTACT

[email protected]

+393397681623

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Collaborators

  • Catholic University of the Sacred Heart
  • Societa Italiana Anestesia Analgesia Rianimazione e Terapia Intensiva

Registry information

Official study title

Helmet Noninvasive Ventilation vs. Continuous Positive Airway Pressure vs. High-flow Nasal Oxygen as First-line Treatment of Acute Hypoxemic Respiratory Failure (HENIVOT2). An Open-label, Multicentre Randomized Trial

Acronym: HENIVOT2

Important dates

Study start
2022
Primary completion
2025
Study completion
2026
First posted
Oct 22, 2021
Registry last updated
Sep 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.